

19

Volume 12, Number 1

compared with placebo (SMD, e0.35; 95% CI, e0.54 to
e0.17; 12 studies; 2232 participants). Thirty-seven studies
reported on adverse events; the most frequent were
gastrointestinal symptoms. Findings for speciﬁc groups
of VADs were limited due to small study numbers in
some